Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Using Apollo Neuro in Autistic Children With Self-Injurious Behavior

NCT: NCT07648420 · NOT_YET_RECRUITING

NCT IDNCT07648420
StatusNOT_YET_RECRUITING
Start Date2026-12
Completion2027-11
SponsorVirginia Commonwealth University (OTHER)
First posted
Last updated

Brief Summary

This study will evaluate the feasibility and acceptability of the Apollo Neuro, a wearable vibrotactile sensory device, in autistic children who engage in self-injurious behavior (SIB). Participants will wear the device for at least 3 hours per day over a 30-35 day period with caregiver support. Outcomes will include adherence to device use, caregiver-reported feasibility and acceptability, and descriptive characterization of caregiver-reported self- injurious and repetitive behaviors during the study period. This preliminary, single-group study is not designed to evaluate efficacy and will inform the design of future controlled trials.

Frequently Asked Questions

What is Using Apollo Neuro in Autistic Children With Self-Injurious Behavior?

Using Apollo Neuro in Autistic Children With Self-Injurious Behavior is a clinical trial registered under NCT07648420. Current status: NOT_YET_RECRUITING.

What is the status of NCT07648420?

The current status of NCT07648420 (Using Apollo Neuro in Autistic Children With Self-Injurious Behavior) is: NOT_YET_RECRUITING.

When did Using Apollo Neuro in Autistic Children With Self-Injurious Behavior start?

Using Apollo Neuro in Autistic Children With Self-Injurious Behavior started on 2026-12.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.